The latest announcement is out from Imunon (IMNN).
Imunon, Inc. has announced the appointment of Stacy R. Lindborg, Ph.D., a renowned biostatistician with nearly three decades of experience in the pharmaceutical and biotech industries, as their new President and CEO starting May 13, 2024. Dr. Lindborg, who has made significant contributions to R&D and regulatory affairs, will receive a $567,000 annual salary, performance bonuses, and significant stock options. Her proven track record in guiding products from early development to commercial launch is expected to be a valuable asset to Imunon’s leadership team.
See more insights into IMNN stock on TipRanks’ Stock Analysis page.
